How were new medicines discovered?

[1]  C. Lindsley,et al.  Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. , 2013, Drug Discovery Today : Technologies.

[2]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[3]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[4]  R. King,et al.  Vigilance and validation: Keys to success in RNAi screening. , 2011, ACS chemical biology.

[5]  P. Hergenrother,et al.  Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. , 2011, ACS chemical biology.

[6]  R M Pruss,et al.  Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. , 2010, CNS & neurological disorders drug targets.

[7]  J. Coe,et al.  Chapter 16. Varenicline (Chantix): An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2010 .

[8]  P. Tonge,et al.  Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.

[9]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[10]  Marc Bickle,et al.  The beautiful cell: high-content screening in drug discovery , 2010, Analytical and bioanalytical chemistry.

[11]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[12]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[13]  David J Newman,et al.  The odyssey of marine pharmaceuticals: a current pipeline perspective. , 2010, Trends in pharmacological sciences.

[14]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[15]  J. Changeux.  Allosteric receptors: from electric organ to cognition. , 2010, Annual review of pharmacology and toxicology.

[16]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[17]  H. Fozzard,et al.  Using Lidocaine and Benzocaine to Link Sodium Channel Molecular Conformations to State-Dependent Antiarrhythmic Drug Affinity , 2009, Circulation research.

[18]  J. Uitdehaag,et al.  The X-ray Structure of RU486 Bound to the Progesterone Receptor in a Destabilized Agonistic Conformation , 2009, The Journal of Biological Chemistry.

[19]  B. Monk,et al.  Green tea catechins for treatment of external genital warts. , 2009, American journal of obstetrics and gynecology.

[20]  Kenneth A. Johnson,et al.  Role of Induced Fit in Enzyme Specificity: A Molecular Forward/Reverse Switch* , 2008, Journal of Biological Chemistry.

[21]  Frank Schluenzen,et al.  The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning , 2008, Proceedings of the National Academy of Sciences.

[22]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[23]  G. Vassart,et al.  Non-peptide arginine-vasopressin antagonists: the vaptans , 2008, The Lancet.

[24]  Sten Ohlson,et al.  Designing transient binding drugs: a new concept for drug discovery. , 2008, Drug discovery today.

[25]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[26]  K. Lyseng-Williamson,et al.  Nelarabine , 2008, Drugs.

[27]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[28]  Charles Flexner,et al.  HIV drug development: the next 25 years , 2007, Nature Reviews Drug Discovery.

[29]  S. Lipton.  Pathologically activated therapeutics for neuroprotection , 2007, Nature Reviews Neuroscience.

[30]  C. Schnell,et al.  Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. , 2007, Journal of medicinal chemistry.

[31]  R. Di Fabio,et al.  Neurokinin 1 receptor antagonists--current prospects. , 2007, Current opinion in drug discovery & development.

[32]  D. Kuter.  New thrombopoietic growth factors. , 2007, Blood.

[33]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[34]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[35]  D. Kuritzkes,et al.  Chemokine antagonists as therapeutics: focus on HIV-1. , 2007, Annual review of medicine.

[36]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[37]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[38]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[39]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[40]  A. Manolis,et al.  Rethinking target discovery in polygenic diseases. , 2006, Current topics in medicinal chemistry.

[41]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[42]  Michael A. Rogawski,et al.  Diverse mechanisms of antiepileptic drugs in the development pipeline , 2006, Epilepsy Research.

[43]  Joachim Mueller,et al.  Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections , 2006, Expert opinion on pharmacotherapy.

[44]  E. Nemeth.  Misconceptions About Calcimimetics , 2006, Annals of the New York Academy of Sciences.

[45]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[46]  G. Vauquelin,et al.  Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[47]  D. Swinney,et al.  Biochemical Mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety. , 2006, Current topics in medicinal chemistry.

[48]  S. Lipton.  Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[49]  Sarah M. Gaffney,et al.  Ranolazine, a Novel Agent for Chronic Stable Angina , 2006, Pharmacotherapy.

[50]  Michael Williams,et al.  Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? , 2005, Biochemical pharmacology.

[51]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[52]  Daniel J Buysse,et al.  Fresh from the pipeline: Ramelteon. , 2005, Nature reviews. Drug discovery.

[53]  C. Figueroa,et al.  Basolateral localization of native ClC-2 chloride channels in absorptive intestinal epithelial cells and basolateral sorting encoded by a CBS-2 domain di-leucine motif , 2005, Journal of Cell Science.

[54]  T. Ratliff.  Innovations and Challenges in Renal Cancer: Consensus Statement From the First International Conference , 2005 .

[55]  J. Heym,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[56]  T. Kenakin,et al.  The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.

[57]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[58]  J. Cuppoletti,et al.  SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. , 2004, American journal of physiology. Cell physiology.

[59]  D. Swinney,et al.  Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.

[60]  C. Deacon.  Therapeutic strategies based on glucagon-like peptide 1. , 2004, Diabetes.

[61]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[62]  N. Blau,et al.  The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 2004, Molecular genetics and metabolism.

[63]  W. Waud,et al.  Purine nucleoside antimetabolites in development for the treatment of cancer. , 2004, Current opinion in investigational drugs.

[64]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[65]  D. Harrison,et al.  Structure of the ferrous form of (4-hydroxyphenyl)pyruvate dioxygenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC. , 2004, Biochemistry.

[66]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[67]  B. Chaitman,et al.  Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. , 2004, Journal of the American College of Cardiology.

[68]  B. Chaitman,et al.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.

[69]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[70]  C. M. Stellrecht,et al.  Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. , 2003, Blood.

[71]  M. Kavana,et al.  Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. , 2003, Biochemistry.

[72]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[73]  G. Pastores,et al.  Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1 , 2003, Expert opinion on investigational drugs.

[74]  A. Roscher,et al.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. , 2002, The New England journal of medicine.

[75]  N. Perico,et al.  New therapeutics that antagonize endothelin: promises and frustrations , 2002, Nature Reviews Drug Discovery.

[76]  S. Hinuma,et al.  Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. , 2002, Journal of medicinal chemistry.

[77]  M. Billah,et al.  Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. , 2002, European journal of pharmacology.

[78]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[79]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[80]  M. Samama,et al.  Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. , 2002, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[81]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[82]  A. Sommer,et al.  Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. , 2001, Cancer research.

[83]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[84]  Stanley B. Brown,et al.  Verteporfin: a milestone in opthalmology and photodynamic therapy , 2001, Expert opinion on pharmacotherapy.

[85]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[86]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[87]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[88]  F. Tally,et al.  Development of daptomycin for gram-positive infections. , 2000, Journal of Antimicrobial Chemotherapy.

[89]  K. Breithaupt-Grögler,et al.  Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man , 2000, The Journal of pharmacy and pharmacology.

[90]  R. Schmitz,et al.  Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. , 2000, The Journal of pharmacology and experimental therapeutics.

[91]  K. Jain.  An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development , 2000, Expert opinion on investigational drugs.

[92]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[93]  R. Kendell.  The next 25 years , 2000, British Journal of Psychiatry.

[94]  S. Kure,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 1999, The Journal of pediatrics.

[95]  D. Shinabarger.  Mechanism of action of the oxazolidinone antibacterial agents. , 1999, Expert opinion on investigational drugs.

[96]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[97]  T. Witek,et al.  Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. , 1999, Life sciences.

[98]  E. Lock,et al.  From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug , 1998, Journal of Inherited Metabolic Disease.

[99]  J. Gustafsson.  Raloxifene: Magic bullet for heart and bone? , 1998, Nature Medicine.

[100]  T. Kikuchi,et al.  Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. , 1998, Journal of medicinal chemistry.

[101]  S. London,et al.  Mifepristone (RU486): a review. , 1997, Fertility and sterility.

[102]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[103]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[104]  R A Rifkind,et al.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[105]  K. Yamada,et al.  Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. , 1996, The Journal of pharmacology and experimental therapeutics.

[106]  J. Wilson,et al.  2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. , 1995, Cancer research.

[107]  S. Morita,et al.  7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[108]  R. Burrier,et al.  Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. , 1995, Atherosclerosis.

[109]  K. Netter,et al.  Pharmacologic analysis of drug-receptor interaction , 1994 .

[110]  G. Koob,et al.  Dopamine receptor agonists, partial agonists and psychostimulant addiction. , 1994, Trends in pharmacological sciences.

[111]  R. Dwek,et al.  N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.

[112]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[113]  K. Valentino,et al.  A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[114]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[115]  J. Gobert,et al.  ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. , 1992, European journal of pharmacology.

[116]  D. Schmatz,et al.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin , 1992, Antimicrobial Agents and Chemotherapy.

[117]  D. Katz,et al.  Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[118]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[119]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[120]  J. Butterworth,et al.  Molecular Mechanisms of Local Anesthesia: A Review , 1990, Anesthesiology.

[121]  J. Bormann.  Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. , 1989, European journal of pharmacology.

[122]  K. Dan,et al.  N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2. , 1989, Journal of medicinal chemistry.

[123]  P. Hadváry,et al.  Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. , 1988, The Biochemical journal.

[124]  K. Dan,et al.  N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. , 1988, Journal of medicinal chemistry.

[125]  D. Dolphin,et al.  Preliminary studies on a more effective phototoxic agent than hematoporphyrin. , 1987, Journal of the National Cancer Institute.

[126]  P. Hadváry,et al.  Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. , 1987, The Journal of antibiotics.

[127]  R. Maurer,et al.  Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. , 1987, The Journal of antibiotics.

[128]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[129]  P. Chrétien,et al.  A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? , 1984, Pharmacology Biochemistry and Behavior.

[130]  D. Kerridge,et al.  Echinocandin inhibition of 1,3‐β‐D‐glucan synthase from Candida albicans , 1984 .

[131]  H Maisonneuve,et al.  Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. , 1984, The American journal of tropical medicine and hygiene.

[132]  M. Petitou,et al.  Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.

[133]  T. Kanbe,et al.  Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds. , 1983, Chemical & pharmaceutical bulletin.

[134]  G. Elion,et al.  An enzymic synthesis of purine d-Arabinonucleosides , 1981 .

[135]  G. Teutsch,et al.  Regio and stereospecific synthesis of 11β-substituted 19-norsteroids Influence of 11β-substitution on progesterone receptor affinity — (1) , 1981, Steroids.

[136]  G. Teutsch,et al.  Regio and stereospecific synthesis of 11β substituted 19 norsteroids , 1979 .

[137]  W. Snipes,et al.  Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols , 1979, Antimicrobial Agents and Chemotherapy.

[138]  R. Martel,et al.  Inhibition of the immune response by rapamycin, a new antifungal antibiotic. , 1977, Canadian journal of physiology and pharmacology.

[139]  S. Person,et al.  Inactivation of Lipid-Containing Viruses by Long-Chain Alcohols , 1977, Antimicrobial Agents and Chemotherapy.

[140]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[141]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[142]  P. Majerus,et al.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.

[143]  R. E. Holmes,et al.  The adamantyl group in medicinal agents. IV. Sedative action of 3,5,7-trimethyladamantane-1-carboxamide and related agents. , 1967, Journal of medicinal chemistry.

[144]  F. J. Marshall,et al.  THE ADAMANTYL GROUP IN MEDICINAL AGENTS. I. HYPOGLYCEMIC N-ARYLSULFONYL-N' -ADAMANTYLUREAS. , 1963, Journal of medicinal chemistry.

[145]  Warren Gregory,et al.  A Preliminary Report , 1953 .

[146]  C. Stock,et al.  THE INACTIVATION OF THE VIRUS OF EPIDEMIC INFLUENZA BY SOAPS , 1940, The Journal of experimental medicine.

[147]  D. Swinney,et al.  Applications of Binding Kinetics to Drug Discovery , 2012, Pharmaceutical Medicine.

[148]  M. R. Barbachyn,et al.  Oxazolidinone Antibacterial Agents , 2012 .

[149]  J. Lexchin.  Drug Approval Times and User Fees , 2012, Pharmaceutical Medicine.

[150]  G. Keating.  Azacitidine , 2012, Drugs.

[151]  J. DiMasi,et al.  Competitiveness in follow-on drug R&D: a race or imitation? , 2011, Nature Reviews Drug Discovery.

[152]  Marc Bickle,et al.  High Content Screening in Drug Discovery , 2010 .

[153]  Christopher J. Chang,et al.  Molecular imaging. , 2010, Current opinion in chemical biology.

[154]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[155]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[156]  Yang Wei-we.  A Review on , 2008 .

[157]  G. Plosker,et al.  Fondaparinux , 2008, Drugs & aging.

[158]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[159]  Ramelteon , 2005, Drugs in R&D.

[160]  S. Ohlson,et al.  Screening for Transient Biological Interactions: A New Concept for Drug Discovery , 2005 .

[161]  A. Goldberg.  Introduction to the Proteasome and its Inhibitors , 2004 .

[162]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[163]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.

[164]  E. De Clercq,et al.  Strategies in the design of antiviral drugs , 2002, Nature reviews. Drug discovery.

[165]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.

[166]  B. O’Malley,et al.  FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent , 2000, Nature Cell Biology.

[167]  M. Yudkoff.  Diseases of Amino Acid Metabolism , 1999 .

[168]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[169]  Y. Yanagihara,et al.  Immunopharmacological studies on TBX, a new antiallergic drug (3). Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. , 1989, Japanese journal of pharmacology.

[170]  T. Kikuchi,et al.  7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. , 1988, Life sciences.

[171]  Y. Yanagihara,et al.  Immunopharmacological studies on TBX, a new antiallergic drug (1). Inhibitory effects on passive cutaneous anaphylaxis in rats and guinea pigs. , 1988, Japanese journal of pharmacology.

[172]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[173]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[174]  T. Karasawa,et al.  3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. , 1980, Arzneimittel-Forschung.

[175]  A. Fersht.  Enzyme structure and mechanism , 1977 .

[176]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[177]  G. Pincus.  The control of fertility , 1965 .

[178]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[179]  D. Robertson,et al.  Le Journal Canadien Des Sciences Neurologiques Experimental Porphyric Neuropathy: a Preliminary Report , 2022 .

[180]  R. Segurado,et al.  A Randomized Controlled Trial , 2022 .